Selecta Biosciences (SELB) Tops Q2 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Selecta Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update
August 12, 2021 8:00 AM EDTIND filing for wholly owned gene therapy program, SEL-302 (MMA-101, in combination with ImmTOR) in methylmalonic acidemia (MMA) expected during the third quarter of 2021; Manufacturing issue has been resolved, with a new completed lot undergoing final release testingSEL-399 (empty AAV8 capsid with ImmTOR) study on track with topline data expected in the fourth quarter of 2021Selecta achieved $3 million milestone payment from Sarepta Therapeutics related to successfully meeting the criteria for a preclinical studyAs of June 30, 2021, Selecta had approximately $151.5 million in cash, cash equivalents, and marketable securities which is expected to... More
